Search
Menu
Home
Sources
About
Contacts
Raseglurant
Raseglurant
is a
negative allosteric modulator
of the mGlu
5
receptor
and
derivative
of
MPEP
which was
under development
by
Addex Therapeutics
for the
treatment
of
migraine
,
gastroesophageal reflux disease
, and
dental anxiety
. It
reached
phase II
clinical trials
for all of the aforementioned
indications
before being discontinued due to the
observation
of possible
predictive
signs
of
hepatotoxicity
in
patients
with
long-term
use.
